Executives at Teva Pharmaceutical Industries Ltd., the world's biggest generic drugmaker, keep dropping hints that they're ready to make a large acquisition. After Chief Executive Officer Erez Vigodman said last month that Teva, which is Israel's largest publicly traded company, would shift to an "inorganic growth" strategy, analysts churned out a flurry of research notes speculating on potential acquisition targets.